Aeterna presents data on AEZS-108 Phase 2 study for endometrial malignancy at EORTC-NCI-AACR Symposium Aeterna Zentaris Inc. The trial was executed by the German AGO Research Group and centers in Bulgaria. The presentation was created by Prof follow this site . The security and efficacy of AEZS-108 inside our study on advanced endometrial cancer was extremely encouraging, commented Prof. We should remember that we used AEZS-108 as an individual agent treatment only, and achieved good prices of objective response and disease stabilization even now. Importantly from the patients' perspective, overall survival was very similar to what provides been reported with more aggressive and less well tolerated combination chemotherapy regimens.
Aeterna enters into agreements to transfer manufacturing permit for Cetrotide to Merck KGaA Aeterna Zentaris Inc.5 million, or around $3.2 million and certain other obligations.P. . With the transfer of manufacturing rights to Merck Serono, Aeterna Zentaris remains centered on its Phase 3 trial in endometrial Stage and cancer 2 trials in breasts, prostate and bladder malignancy with AEZS-108, its upcoming NDA filing for AEZS-130 as an oral diagnostic check for growth hormone deficiency in adults, and also its earlier-stage oncology substances, including AEZS-120. The usage of the name ‘Merck’ and ‘Merck Serono’ in this press release refers to Merck KGaA of Darmstadt, Germany. In North America, Merck KGaA operates under the umbrella brand EMD.